Emergent BioSolutions wins $235.8M DoD contract for BioThrax anthrax vaccine

Emergent BioSolutions Inc.

IDIQ contract with U.S. DoD and JPEO-CBRND valued up to $235.8M to supply BioThrax for military PrEP.
Contract includes 5-year base ending Sep 30, 2028, plus a 5-year option extending to Sep 30, 2033.
Guaranteed minimum purchase of $20.1M in first year; estimated at least $20M per year thereafter.
Paul Williams, senior VP products head, notes contract reinforces Emergent's medical countermeasures portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.